Prophylaxis Of Deep Vein Thrombosis- Fondaparinux is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE): In patients undergoing hip fracture surgery, including extended prophylaxis; In patients undergoing hip replacement surgery; In patients undergoing knee replacement surgery; In patients undergoing abdominal surgery who are at risk for thromboembolic complications. Treatment Of Acute Deep Vein Thrombosis: Fondaparinux is indicated for the treatment of acute deep vein thrombosis when administered in conjunction with warfarin sodium. Treatment Of Acute Pulmonary Embolism: Fondaparinux is indicated for the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital.
Parenteral anti-coagulants
The antithrombotic activity of Fondaparinux Sodium is the result of selective inhibition of Factor Xa. By selectively binding to antithrombin III (ATIII), Fondaparinux Sodium potentiates (about 300 times) the innate neutralization of Factor Xa by ATIII. Neutralization of Factor Xa interrupts the blood coagulation cascade and thus inhibits thrombin formation and thrombus development. Fondaparinux Sodium does not inactivate thrombin (activated Factor II) and has no known effect on platelet function. At the recommended dose, Fondaparinux Sodium does not affect fibrinolytic activity or bleeding time.
Prophylaxis of deep vein thrombosis:
Fondaparinux 2.5 mg subcutaneously once daily after hemostasis has been established.
The initial dose should be given no earlier than 6 to 8 hours after surgery and continued for 5 to 9 days.
For patients undergoing hip fracture surgery, extended prophylaxis up to 24 additional days is recommended.
Treatment of deep vein thrombosis and pulmonary embolism:
Fondaparinux 5 mg (body weight <50 kg)
Fondaparinux 7.5 mg (50 to 100 kg) or
Fondaparinux 10 mg (>100 kg) subcutaneously once daily.
Treatment should continue for at least 5 days until INR 2 to 3 achieved with warfarin sodium.
Pediatric Use: Safety and effectiveness of Fondaparinux Sodium in pediatric patients have not been established.
Geriatric Use: In clinical trials, the efficacy of Fondaparinux Sodium in the elderly (65 years or older) was similar to that seen in patients younger than 65 years; however, serious adverse events increased with age.
Use in renal or hepatic impairment: The risk of bleeding is increased with reduced renal or hepatic function.
Discontinue agents that may enhance the risk of hemorrhage prior to initiation of therapy with Fondaparinux Sodium unless essential. If co-administration is necessary, monitor patients closely for hemorrhage.
Fondaparinux Sodium is contraindicated in the following conditions:
Severe renal impairment (creatinine clearance <30 mL/min)
Active major bleeding
Bacterial endocarditis
Thrombocytopenia
Body weight <50 kg (venous thromboembolism [VTE] prophylaxis only)
History of serious hypersensitivity reaction to Fondaparinux Sodium
Fondaparinux Sodium is contraindicated in the following conditions:
Severe renal impairment (creatinine clearance <30 mL/min)
Active major bleeding
Bacterial endocarditis
Thrombocytopenia
Body weight <50 kg (venous thromboembolism [VTE] prophylaxis only)
History of serious hypersensitivity reaction to Fondaparinux Sodium
The most common adverse reactions associated with the use of Fondaparinux Sodium are-bleeding complications, mild local irritation (injection site bleeding, rash and pruritus) following subcutaneous injection, anemia, insomnia, hypokalemia, dizziness, hypotension, confusion, bullous eruption, hematoma & post-operative hemorrhage.
Pregnancy Category B. It is not known whether Fondaparinux sodium is excreted in human milk. Caution should be exercised when Fondaparinux Sodium is administered to a nursing woman.
Store below 25° C. Do not freeze. Keep the medicine out of reach of children.
.png&w=384&q=75)